Core Viewpoint - Scilex Holding Company has acquired an exclusive worldwide license for Datavault AI's AI-driven technology, aimed at creating a Biotech Exchange platform to tokenize and monetize biotech assets, marking a significant advancement in the commercialization of biotech innovations [1][4]. Group 1: Licensing Agreement and Financial Implications - Scilex will pay a non-refundable upfront license fee of $10 million, divided into four equal installments of $2.5 million each, due by the end of September 2026 [5]. - Datavault AI could earn up to $2.55 billion in sales milestone payments based on the achievement of specific sales milestones [5]. Group 2: Market Opportunity and Tokenization Potential - Scilex estimates the opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug and diagnostic sales, which could provide an alternative funding mechanism for companies to develop and commercialize products [3]. - The advanced data platform may also lead to the creation of a Pharmaceutical Exchange platform, potentially revolutionizing the pharmaceutical industry [2]. Group 3: Technology and Intellectual Property - The license includes Datavault AI's key pending patent for "Platform and Method for Tokenizing DNA Data," which provides a framework for securely tokenizing and exchanging sensitive genetic information [4]. - Datavault AI's technology suite includes multiple issued and pending patents that support the infrastructure for a secure and efficient Biotech Exchange, ensuring compliance and privacy standards [4][7].